A study of up to 433,390 UK adults, led by The University of Manchester, has linked being under and overweight at birth with poorer hearing, vision and cognition in middle age.
Ethnic, racial & socioeconomic disparities in retinoblastoma in children
Ethnic, racial and socioeconomic disparities appear to exist among children with retinoblastoma, a once uniformly fatal but now treatable eye cancer, and those disparities are associated with…
Uncategorized
Aerpio Appoints Steve Pakola, M.D. as Chief Medical Officer
CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that Steve Pakola, M.D. has been appointed as the company’s first Chief Medical Officer. Dr. Pakola will lead the advancement of Aerpio’s development pipeline, including lead therapeutic candidate, AKB-9778. Dr. Pakola will report to Aerpio’s President and CEO Joseph Gardner, and his appointment is effective immediately. “Steve brings 20
Uncategorized
Publication Exclusive: Woman presents with bilateral progressive ptosis
A 72-year-old Armenian woman was referred to the oculoplastics clinic at the New England Eye Center for evaluation of bilateral ptosis. She noticed gradual onset of drooping eyelids over the course of many years.The patient’s medical history was significant only for medically well controlled hypertension and hypercholesterolemia. She was pseudophakic and had lattice corneal dystrophy. Of note, two of her children had lattice corneal dystrophy. Her brother and two children also had similar ptosis. She denied trauma, eye rubbing or chronic contact lens wear. She had no other infectious, neoplastic (Read more...)
Envisia’s ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial
Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company’s lead product candidate, ENV515 (travopro…
Scientists test new gene therapy for vision loss from a mitochondrial disease
NIH-funded study shows success in targeting mitochondrial DNA in miceResearchers funded by the National Institutes of Health have developed a novel mouse model for the vision disorder Leber…